Skip to main content

Paxlovid News

Paxlovid May Offer Little Benefit for Vaccinated Older Adults

THURSDAY, March 6, 2025 --  The antiviral drug Paxlovid may not offer much protection against COVID-related hospitalizations or deaths for vaccinated older adults after all. Research published ...

Extended Nirmatrelvir/Ritonavir Beneficial for Some With Long COVID

WEDNESDAY, Jan. 8, 2025 – Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist, according to a case series...

Despite Previous Data, Paxlovid May Be Useful for Long Covid After All

WEDNESDAY, Jan. 8, 2024 – The antiviral pill Paxlovid might help some patients who are suffering from long COVID. A five-day course of Paxlovid is known to help limit symptoms and shorten illness in...

FDA Approves Paxlovid (nirmatrelvir tablets and ritonavir tablets) for Adult Patients at High Risk of Progression to Severe COVID-19

NEW YORK--(BUSINESS WIRE) May 25, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) for t...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

COVID-19

Paxlovid patient information at Drugs.com